Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2035) 2035
Publication (265) 265
Book Review (39) 39
Book Chapter (23) 23
Conference Proceeding (8) 8
Book / eBook (5) 5
Data Set (1) 1
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1584) 1584
index medicus (1109) 1109
antifungal agents - therapeutic use (911) 911
male (759) 759
invasive aspergillosis (696) 696
female (673) 673
invasive pulmonary aspergillosis (585) 585
infectious diseases (565) 565
aspergillosis (564) 564
middle aged (535) 535
microbiology (519) 519
aspergillosis - drug therapy (473) 473
adult (468) 468
voriconazole (415) 415
pulmonary aspergillosis (409) 409
pharmacology & pharmacy (403) 403
fungal-infections (372) 372
diagnosis (359) 359
aged (353) 353
animals (343) 343
amphotericin-b (328) 328
treatment outcome (320) 320
risk factors (301) 301
antifungal agents - administration & dosage (298) 298
mycoses (298) 298
immunocompromised host (295) 295
invasive pulmonary aspergillosis - drug therapy (292) 292
aspergillus (267) 267
liposomal amphotericin-b (266) 266
antifungal agents (264) 264
antifungal agents - pharmacology (261) 261
health aspects (259) 259
immunology (256) 256
mycology (256) 256
invasive fungal-infections (249) 249
transplantation (248) 248
hematology (242) 242
therapy (236) 236
infections (231) 231
amphotericin b - therapeutic use (225) 225
mycoses - drug therapy (225) 225
adolescent (208) 208
aspergillosis - microbiology (207) 207
triazoles - therapeutic use (207) 207
epidemiology (204) 204
mortality (202) 202
care and treatment (198) 198
retrospective studies (196) 196
fungal infections (195) 195
aspergillosis - diagnosis (193) 193
itraconazole (192) 192
caspofungin (191) 191
research (190) 190
neutropenia (189) 189
child (187) 187
mice (179) 179
oncology (179) 179
invasive pulmonary aspergillosis - diagnosis (176) 176
amphotericin b (175) 175
neutropenic patients (175) 175
aspergillus fumigatus (173) 173
infection (160) 160
microbial sensitivity tests (160) 160
aspergillus fumigatus - drug effects (159) 159
cancer (158) 158
antifungal agents - adverse effects (157) 157
fungi (157) 157
fumigatus (155) 155
lung diseases, fungal - drug therapy (154) 154
antifungal therapy (149) 149
drug therapy, combination (146) 146
pharmacokinetics (145) 145
antifungal agents - pharmacokinetics (142) 142
invasive pulmonary aspergillosis - microbiology (142) 142
disease (140) 140
amphotericin b - administration & dosage (139) 139
lipopeptides (139) 139
stem-cell transplantation (138) 138
young adult (136) 136
efficacy (134) 134
respiratory system (134) 134
galactomannan (133) 133
risk-factors (132) 132
drug therapy (129) 129
veterinary sciences (128) 128
echinocandins - therapeutic use (127) 127
immunocompromised patients (127) 127
leukemia (127) 127
echinocandins (124) 124
prophylaxis (124) 124
patients (122) 122
aspergillus fumigatus - isolation & purification (120) 120
pyrimidines - therapeutic use (119) 119
cell transplant recipients (115) 115
disease models, animal (115) 115
medicine (115) 115
tomography, x-ray computed (115) 115
fluconazole (114) 114
neutropenia - complications (114) 114
aspergillus - isolation & purification (112) 112
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1972) 1972
French (28) 28
Spanish (27) 27
German (12) 12
Japanese (10) 10
Chinese (6) 6
Turkish (2) 2
Lithuanian (1) 1
Polish (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pulmonary aspergillosis: A clinical review
by Kousha, M and Tadi, R and Soubani, A.O
European Respiratory Review, ISSN 0905-9180, 09/2011, Volume 20, Issue 121, pp. 156 - 174
Aspergillus is a mould which may lead to a variety of infectious, allergic diseases depending on the host's immune status or pulmonary structure. Invasive... 
Diagnosis | Management | Pulmonary | Risk factors | Aspergillosis | Invasive Pulmonary Aspergillosis - drug therapy | Predictive Value of Tests | Pulmonary Aspergillosis - drug therapy | Aspergillosis, Allergic Bronchopulmonary - microbiology | Risk Assessment | Humans | Risk Factors | Treatment Outcome | Pulmonary Aspergillosis - diagnosis | Aspergillosis, Allergic Bronchopulmonary - drug therapy | Pulmonary Aspergillosis - microbiology | Invasive Pulmonary Aspergillosis - diagnosis | Antifungal Agents - therapeutic use | Pulmonary Aspergillosis - epidemiology | Invasive Pulmonary Aspergillosis - microbiology | Aspergillosis, Allergic Bronchopulmonary - diagnosis | Aspergillosis, Allergic Bronchopulmonary - epidemiology | Invasive Pulmonary Aspergillosis - epidemiology | diagnosis | pulmonary | risk factors | management
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text High-frequency Triazole Resistance Found in Nonculturable Aspergillus fumigatus from Lungs of Patients With Chronic Fungal Disease
by David W. Denning and Steven Park and Cornelia Lass-Florl and Marcin G. Fraczek and Marie Kirwan and Robin Gore and Jaclyn Smith and Ahmed Bueid and Caroline B. Moore and Paul Bowyer and David S. Perlin
Clinical Infectious Diseases, ISSN 1058-4838, 5/2011, Volume 52, Issue 9, pp. 1123 - 1129
Background. Oral triazole therapy is well established for the treatment of invasive (IPA), allergic (ABPA), and chronic pulmonary (CPA) aspergillosis and is... 
Polymerase chain reaction | Antifungals | Aspergillus | Azoles | Triazoles | Aspergillosis | Sputum | ARTICLES AND COMMENTARIES | Allergic bronchopulmonary aspergillosis | Aspergillus fumigatus | Genetic mutation | DIAGNOSIS | INFECTIOUS DISEASES | SEVERE ASTHMA | METAANALYSIS | MICROBIOLOGY | ITRACONAZOLE | IMMUNOLOGY | INVASIVE ASPERGILLOSIS | PULMONARY ASPERGILLOSIS | SENSITIZATION | AZOLE RESISTANCE | ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS | PCR | Aspergillus fumigatus - drug effects | Sputum - microbiology | Lung - microbiology | Aspergillosis, Allergic Bronchopulmonary - microbiology | Humans | Aspergillosis, Allergic Bronchopulmonary - drug therapy | Antifungal Agents - therapeutic use | Bronchoalveolar Lavage Fluid - microbiology | Aspergillus fumigatus - isolation & purification | Culture Media | Polymerase Chain Reaction | Aspergillosis, Allergic Bronchopulmonary - epidemiology | Invasive Pulmonary Aspergillosis - epidemiology | Triazoles - therapeutic use | Antifungal Agents - pharmacology | Invasive Pulmonary Aspergillosis - drug therapy | Pulmonary Aspergillosis - drug therapy | DNA, Fungal - analysis | Drug Resistance, Fungal - genetics | Aspergillus fumigatus - genetics | Pulmonary Aspergillosis - microbiology | Triazoles - pharmacology | Pulmonary Aspergillosis - epidemiology | Invasive Pulmonary Aspergillosis - microbiology | Mutation | Chronic Disease | Drug resistance in microorganisms | Usage | Physiological aspects | Causes of | Lung diseases, Fungal | Research | Drug therapy | Health aspects | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)
by Lortholary, O and Gangneux, J.-P and Sitbon, K and Lebeau, B and de Monbrison, F and Le Strat, Y and Coignard, B and Dromer, F and Bretagne, S and French Mycosis Study Grp and French Mycosis Study Group
Clinical Microbiology and Infection, ISSN 1198-743X, 12/2011, Volume 17, Issue 12, pp. 1882 - 1889
A prospective (2005–2007) hospital-based multicentre surveillance of EORTC/MSG-proven or probable invasive aspergillosis (IA) cases whatever the underlying... 
invasive aspergillosis | voriconazole | galactomannan | Epidemiology | outcome | Galactomannan | Invasive aspergillosis | Outcome | Voriconazole | INFECTIOUS DISEASES | MICROBIOLOGY | Aspergillus - classification | Prospective Studies | Humans | Middle Aged | Male | Antifungal Agents - therapeutic use | Incidence | Young Adult | Aged, 80 and over | Aspergillus - isolation & purification | Adult | Female | Seasons | Invasive Pulmonary Aspergillosis - epidemiology | Invasive Pulmonary Aspergillosis - drug therapy | France - epidemiology | Risk Factors | Invasive Pulmonary Aspergillosis - mortality | Drug Therapy, Combination - methods | Hospitals | Invasive Pulmonary Aspergillosis - microbiology | Mannans - blood | Adolescent | Aged | Immunocompromised Host | Analysis | Leukemia | Aspergillosis | Stem cells | Transplantation of organs, tissues, etc | Respiratory tract diseases | Transplantation | Risk factors | Trends | Transplants & implants | Mortality | Cell culture | Risk groups | Lung | stem cell transplantation | Central nervous system | Immunoproliferative diseases | Lipids | Regression analysis | Inflammatory diseases | Seasonal variations | Caspofungin | Geriatrics | Tumors | Life Sciences | Aspergillus | Microbiology and Parasitology | Invasive Pulmonary Aspergillosis | Mannans | Antifungal Agents | Drug Therapy, Combination | France
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis
by Denning, David W and Pleuvry, Alex and Cole, Donald C
Bulletin of the World Health Organization, ISSN 0042-9686, 12/2011, Volume 89, Issue 12, pp. 864 - 872
Objective To estimate the global burden of chronic pulmonary aspergillosis (CPA) after pulmonary tuberculosis (PTB), specifically in cases with pulmonary... 
VORICONAZOLE | SOUTH-AFRICA | RELAPSE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | THERAPY | SERIES | CHRONIC CAVITARY | MULTIDRUG-RESISTANT TUBERCULOSIS | DISEASE | FOLLOW-UP | GOLD MINERS | Invasive Pulmonary Aspergillosis - drug therapy | Risk Assessment - methods | Prevalence | Global Health | Humans | Tuberculosis, Pulmonary - drug therapy | Antifungal Agents - therapeutic use | Incidence | Tuberculosis, Pulmonary - complications | Invasive Pulmonary Aspergillosis - etiology | Epidemiologic Methods | Tuberculosis, Pulmonary - epidemiology | Antitubercular Agents - therapeutic use | Invasive Pulmonary Aspergillosis - epidemiology | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment
by Chowdhary, A and Sharma, C and Meis, J.F.G.M
Journal of Infectious Diseases, ISSN 0022-1899, 2017, Volume 216, Issue suppl_3, pp. S436 - s444
Aspergillus fumigatus remains the most common species in all pulmonary syndromes, followed by Aspergillus flavus which is a common cause of allergic... 
Aspergillus fumigatis | Aspergillus | epidemiology | treatment | fumigatis | azole-esistant aspergillosis | cyp51 mutations | non cyp51 mutations | Azole-resistant aspergillosis | resistance mechanisms | UNITED-STATES | INFECTIOUS DISEASES | azole-resistant aspergillosis | ITRACONAZOLE RESISTANCE | MICROBIOLOGY | IN-VITRO SUSCEPTIBILITY | DRUG-RESISTANCE | IMMUNOLOGY | TR46/Y121F/T289A MUTATION | CYP51A GENE | INVASIVE PULMONARY ASPERGILLOSIS | TRIAZOLE RESISTANCE | CYSTIC-FIBROSIS | HIGH PREVALENCE | Antifungal Agents - pharmacology | Aspergillus fumigatus - drug effects | Invasive Pulmonary Aspergillosis - drug therapy | Bronchitis - epidemiology | Humans | Cytochrome P-450 Enzyme System - metabolism | Tandem Repeat Sequences | Fungal Proteins - genetics | Aspergillosis, Allergic Bronchopulmonary - drug therapy | Invasive Pulmonary Aspergillosis - diagnosis | Bronchitis - diagnosis | Triazoles - pharmacology | Point Mutation | Bronchitis - diet therapy | Cytochrome P-450 Enzyme System - genetics | Drug Resistance, Fungal | Aspergillosis, Allergic Bronchopulmonary - diagnosis | Aspergillosis, Allergic Bronchopulmonary - epidemiology | Fungal Proteins - metabolism | Invasive Pulmonary Aspergillosis - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Diagnosis and Treatment of Pulmonary Aspergillosis Syndromes
by Patterson, Karen C, MD and Strek, Mary E, MD, FCCP
Chest, ISSN 0012-3692, 2014, Volume 146, Issue 5, pp. 1358 - 1368
Both inherited and acquired immunodeficiency and chronic pulmonary disease predispose to the development of a variety of pulmonary syndromes in response to... 
Pulmonary/Respiratory | BRONCHOALVEOLAR LAVAGE FLUID | INTERFERON-GAMMA | INVASIVE FUNGAL DISEASE | INTENSIVE-CARE-UNIT | CHRONIC CAVITARY | RESPIRATORY SYSTEM | ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS | RANDOMIZED CONTROLLED-TRIAL | CYSTIC-FIBROSIS | CRITICALLY-ILL PATIENTS | CLINICAL-SIGNIFICANCE | CRITICAL CARE MEDICINE | Diagnosis, Differential | Pulmonary Aspergillosis - drug therapy | Humans | Aspergillus - isolation & purification | Pulmonary Aspergillosis - diagnosis | Pulmonary Aspergillosis - microbiology | Antifungal Agents - therapeutic use | Aspergillus | Care and treatment | Corticosteroids | Pulmonary aspergillosis | Analysis | Immunodeficiency | Dosage and administration | Research | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The spectrum of pulmonary aspergillosis
by Kanj, Amjad and Abdallah, Nadine and Soubani, Ayman O
Respiratory Medicine, ISSN 0954-6111, 08/2018, Volume 141, pp. 121 - 131
Notable progress has been made in the past years in the classification, diagnosis and treatment of pulmonary aspergillosis. New criteria were proposed by the... 
Aspergillus | Chronic pulmonary aspergillosis | Invasive aspergillosis | Pulmonary aspergillosis | Allergic bronchopulmonary aspergillosis | BRONCHOALVEOLAR LAVAGE FLUID | SEVERE ASTHMA | CARDIAC & CARDIOVASCULAR SYSTEMS | COLONY-STIMULATING FACTOR | CHRONIC GRANULOMATOUS-DISEASE | RANDOMIZED-TRIAL | CLINICAL CHARACTERISTICS | INVASIVE FUNGAL-INFECTIONS | RESPIRATORY SYSTEM | GALACTOMANNAN ANTIGEN | CYSTIC-FIBROSIS | Invasive Pulmonary Aspergillosis - drug therapy | Recurrence | Triazoles - administration & dosage | Pulmonary Aspergillosis - drug therapy | Prognosis | Pyridines - administration & dosage | Humans | Environmental Exposure - prevention & control | Pulmonary Aspergillosis - diagnosis | Aspergillosis, Allergic Bronchopulmonary - drug therapy | Pulmonary Aspergillosis - microbiology | Invasive Pulmonary Aspergillosis - diagnosis | Antifungal Agents - therapeutic use | Environmental Exposure - adverse effects | Fungi | Nitriles - administration & dosage | Pulmonary Aspergillosis - epidemiology | Aspergillus - isolation & purification | Aspergillosis, Allergic Bronchopulmonary - diagnosis | Nitriles - therapeutic use | Pyridines - therapeutic use | Triazoles - therapeutic use | Sleep disorders | Medical colleges | Triazoles | Communicable diseases | Cystic fibrosis | Respiratory agents | Drug approval | Risk factors | Therapy | Regulatory agencies | Medical imaging | Microbiology | Mycology | Medical treatment | Medical services | Molds | Infections | Medical diagnosis | Patients | Asthma | Infectious diseases | Classification | Aspergillosis | Chronic obstructive pulmonary disease | Diagnosis | Clinical microbiology | Immune system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus
by Verweij, Paul E and Ananda-Rajah, Michelle and Andes, David and Arendrup, Maiken C and Brüggemann, Roger J and Chowdhary, Anuradha and Cornely, Oliver A and Denning, David W and Groll, Andreas H and Izumikawa, Koichi and Kullberg, Bart Jan and Lagrou, Katrien and Maertens, Johan and Meis, Jacques F and Newton, Pippa and Page, Iain and Seyedmousavi, Seyedmojtaba and Sheppard, Donald C and Viscoli, Claudio and Warris, Adilia and Donnelly, J. Peter
Drug Resistance Updates, ISSN 1368-7646, 2015, Volume 21-22, pp. 30 - 40
Abstract An international expert panel was convened to deliberate the management of azole-resistant aspergillosis. In culture-positive cases, in vitro... 
Infectious Disease | Hematology, Oncology and Palliative Medicine | Chronic aspergillosis | Invasive aspergillosis | Aspergillus fumigatus | Azole resistance | Voriconazole | BRONCHOALVEOLAR LAVAGE FLUID | TR34/L98H MUTATIONS | WILD-TYPE | CHRONIC PULMONARY ASPERGILLOSIS | CYP51A GENE | LIPOSOMAL AMPHOTERICIN-B | PHARMACODYNAMIC TARGET DETERMINATION | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | ANTIFUNGAL THERAPY | Antifungal Agents - pharmacology | Aspergillus fumigatus - drug effects | Azoles - administration & dosage | Pulmonary Aspergillosis - drug therapy | Drug Resistance, Multiple, Fungal | Humans | Azoles - pharmacology | Pulmonary Aspergillosis - microbiology | Microbial Sensitivity Tests | Aspergillus fumigatus - isolation & purification | Aspergillosis - microbiology | Drug Design | Drug Therapy, Combination | Antifungal Agents - administration & dosage | Drug Resistance, Fungal | Aspergillosis - drug therapy | Mycoses | Antiparasitic agents | Amphotericin B | Triazoles | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-d-Glucan, and Consequences of Delayed Antifungal Therapy
by William W. Hope and Vidmantas Petraitis and Ruta Petraitiene and Tamarra Aghamolla and John Bacher and Thomas J. Walsh
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2010, Volume 54, Issue 11, pp. 4879 - 4886
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
MORTALITY | CANDIDA-ALBICANS | FORMULATIONS | NEUTROPENIA | INTRAPULMONARY PHARMACOKINETICS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | SERUM | AMPHOTERICIN-B | COMBINATION | FLUCONAZOLE | Aspergillus fumigatus - drug effects | Invasive Pulmonary Aspergillosis - drug therapy | Rabbits | Deoxycholic Acid - therapeutic use | Aspergillus fumigatus - pathogenicity | Antifungal Agents - therapeutic use | beta-Glucans - metabolism | Invasive Pulmonary Aspergillosis - metabolism | Animals | Mannans - metabolism | Aspergillus fumigatus - metabolism | Amphotericin B - therapeutic use | Drug Combinations | Experimental Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Chronic pulmonary aspergillosis
by Schweer, K.E and Bangard, C and Hekmat, K and Cornely, O.A
Mycoses, ISSN 0933-7407, 2014, Volume 57, Issue 5, pp. 257 - 270
Chronic pulmonary aspergillosis (CPA) is a group of consuming diseases usually presenting with prolonged and relapsing cough, dyspnoea and weight loss. Acute... 
Chronic cavitary pulmonary aspergillosis | Chronic necrotising pulmonary aspergillosis | Chronic fibrosing pulmonary aspergillosis | Semi-invasive aspergillosis | Complex aspergilloma | Subacute aspergillosis | GLOBAL BURDEN | PROGNOSTIC-FACTORS | subacute aspergillosis | INTERSTUDY REPRODUCIBILITY | CYP51A GENE | DERMATOLOGY | chronic necrotising pulmonary aspergillosis | CHRONIC NECROTIZING ASPERGILLOSIS | chronic fibrosing pulmonary aspergillosis | CHRONIC CAVITARY | LATERAL-FLOW DEVICE | AZOLE RESISTANCE | semi-invasive aspergillosis | CASE SERIES | complex aspergilloma | MYCOLOGY | HEALTH-STATUS | Pulmonary Aspergillosis - drug therapy | Animals | Humans | Aspergillus - isolation & purification | Aspergillus - genetics | Aspergillus - physiology | Pulmonary Aspergillosis - diagnosis | Pulmonary Aspergillosis - microbiology | Antifungal Agents - therapeutic use
Journal Article
Details down arrow
11. Full Text Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy
by Susan J. Howard and Jodi M. Lestner and Andrew Sharp and Lea Gregson and Joanne Goodwin and Joanne Slater and Jayesh B. Majithiya and Peter A. Warn and William W. Hope
The Journal of Infectious Diseases, ISSN 0022-1899, 5/2011, Volume 203, Issue 9, pp. 1324 - 1332
Background. Posaconazole is a triazole with anti-Aspergillus activity. However, little is known about the utility of posaconazole as primary therapy for... 
Antifungals | Pulmonary alveoli | Aspergillus | Dose response relationship | Animal models | FUNGI | Invasive pulmonary aspergillosis | Drug design | Mice | Mathematical models | Pharmacokinetics | GALACTOMANNAN ANTIGENEMIA | PROPHYLAXIS | INFECTIOUS DISEASES | EFFICACY | NEUTROPENIA | TRIAZOLE | AZOLE RESISTANCE | MICROBIOLOGY | MODEL | IMMUNOLOGY | FUMIGATUS | FLUCONAZOLE | Models, Theoretical | Invasive Pulmonary Aspergillosis - drug therapy | Triazoles - administration & dosage | Animals | Antifungal Agents - pharmacokinetics | Invasive Pulmonary Aspergillosis - microbiology | Male | Triazoles - pharmacokinetics | Antifungal Agents - administration & dosage | Disease Models, Animal | Care and treatment | Dosage and administration | Research | Posaconazole | Aspergillosis | Major and Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights